Wockhardt

{
  "main_header": {
    "sid": 256229,
    "name": "Wockhardt",
    "stock_name": "Wockhardt",
    "full_name": "Wockhardt Ltd",
    "name_url": "stocks-analysis/wockhardt",
    "exchange": 0,
    "exchangecode": "",
    "primexch": 1,
    "country_id": 34,
    "currency": "INR",
    "cmp": "1,638.95",
    "chg": -81.3,
    "chgp": "-4.73%",
    "dir": -1,
    "prev_price": "1,720.25",
    "mcapval": "26,860.00 Cr",
    "mcap": "Small Cap",
    "scripcode": 532300,
    "symbol": "WOCKPHARMA",
    "ind_name": "Pharmaceuticals & Biotechnology",
    "ind_code": 4,
    "indexname": "India SENSEX",
    "isin": "INE049B01025",
    "curr_date": "May 07",
    "curr_time": "",
    "bse_nse_vol": "33.05 lacs",
    "exc_status": "Active",
    "traded_date": "May 07, 2026",
    "traded_date_str": "2026 05 07",
    "score": "",
    "scoreText": "",
    "Live": 1,
    "market_time": 1,
    "is_blur": 1,
    "is_blur_class": "blur-registerF-score-header",
    "is_blur_url": "https://www.marketsmojo.com/mojofeed/register?redirect=/stocks-analysis/wockhardt-256229-0&utm_source=Spage_Header_Score",
    "mojoone": {
      "ismore": 0
    }
  },
  "news": {
    "results": [
      {
        "title": "Wockhardt Ltd Sees Heavy Value Trading Amid Sector Underperformance",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/wockhardt-ltd-sees-heavy-value-trading-amid-sector-underperformance-3979278",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/5/WockhardtLtd_most_active_equities_by_value_3979278.png",
        "date": "2026-05-07 10:00:10",
        "description": "Wockhardt Ltd, a small-cap player in the Pharmaceuticals & Biotechnology sector, witnessed significant trading activity on 7 May 2026, with a total traded value exceeding ₹258 crore. Despite this high-value turnover, the stock underperformed its sector and broader market indices, reflecting a complex interplay of investor sentiment and institutional interest."
      },
      {
        "title": "Wockhardt Ltd Sees Technical Momentum Shift Amid Strong Price Rally",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/wockhardt-ltd-sees-technical-momentum-shift-amid-strong-price-rally-3978677",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/5/WockhardtLtd_technicaldot_3978677.png",
        "date": "2026-05-07 08:01:09",
        "description": "Wockhardt Ltd, a small-cap player in the Pharmaceuticals & Biotechnology sector, has witnessed a notable shift in its technical parameters, signalling a transition from a mildly bearish trend to a sideways momentum. Despite this, the stock has surged impressively, gaining 11.9% in a single day and outperforming the broader Sensex across multiple timeframes, reflecting a complex interplay of bullish and bearish technical indicators."
      },
      {
        "title": "Wockhardt Ltd Valuation Shifts Signal Heightened Price Premium Amid Strong Returns",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/wockhardt-ltd-valuation-shifts-signal-heightened-price-premium-amid-strong-returns-3978616",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/5/WockhardtLtd_valuationdot_3978616.png",
        "date": "2026-05-07 08:00:30",
        "description": "Wockhardt Ltd has witnessed a significant shift in its valuation parameters, moving from an already expensive rating to a very expensive classification. This change comes amid a robust price rally that has seen the stock surge over 11.9% in a single day, raising questions about its price attractiveness relative to historical and peer benchmarks in the Pharmaceuticals & Biotechnology sector."
      },
      {
        "title": "Wockhardt Ltd Sees Robust Trading Activity Amid Strong Price Gains",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/wockhardt-ltd-sees-robust-trading-activity-amid-strong-price-gains-3977406",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/5/WockhardtLtd_most_active_equities_by_value_3977406.png",
        "date": "2026-05-06 10:00:06",
        "description": "Wockhardt Ltd, a small-cap player in the Pharmaceuticals & Biotechnology sector, has emerged as one of the most actively traded stocks by value on 6 May 2026. The stock recorded a significant 7.56% gain on the day, driven by robust institutional participation and a surge in large order flows, signalling renewed investor confidence despite a recent downgrade in its mojo grade."
      },
      {
        "title": "Wockhardt Ltd Surges 7.11% to Day's High of Rs 1650 — Outperforms Sector by 6.14 Percentage Points",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/wockhardt-ltd-hits-intraday-high-with-711-surge-on-6-may-2026-3977366",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/5/WockhardtLtd_priceRelatedfactors_3977366.png",
        "date": "2026-05-06 09:55:44",
        "description": "The Sensex edged up 0.33% on 6 May 2026, while Wockhardt Ltd surged 7.11%, reaching an intraday high of Rs 1650. This 6.14-percentage-point outperformance over the Pharmaceuticals & Biotechnology sector highlights a distinctly stock-specific rally rather than a broad market lift."
      },
      {
        "title": "Are Wockhardt Ltd latest results good or bad?",
        "link": "https://www.marketsmojo.com/news/result-analysis/are-wockhardt-ltd-latest-results-good-or-bad-3976421",
        "imagepath": "",
        "date": "2026-05-05 19:14:29",
        "description": "Wockhardt Ltd's latest financial results for the quarter ended March 2026 highlight a significant operational turnaround for the company. The net profit reached ₹166 crore, reflecting a substantial increase compared to the previous quarter's loss. This marks a notable recovery from prior financial struggles, indicating improved operational efficiency and profitability. \n\nThe company's revenue also showed positive momentum, with net sales of ₹965 crore, representing an 8.67% increase from the previous quarter and a 29.88% year-on-year growth. This growth is attributed to strengthening demand across its pharmaceutical portfolio and enhanced market penetration. The operating margin improved to 23.32%, the highest in recent quarters, showcasing effective cost management and operational leverage.\n\nWockhardt's transformation from a chronic loss-maker to a profitable entity is underscored by its ability to achieve..."
      },
      {
        "title": "Wockhardt Ltd Reports Outstanding Q4 2026 Performance Amid Strong Financial Trend Reversal",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/wockhardt-ltd-reports-outstanding-q4-2026-performance-amid-strong-financial-trend-reversal-3975933",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/5/WockhardtLtd_fintrenddot_3975933.png",
        "date": "2026-05-05 11:00:05",
        "description": "Wockhardt Ltd has delivered an exceptional quarterly performance for March 2026, marking a significant turnaround in its financial trend from very positive to outstanding. The pharmaceutical company’s latest results showcase robust revenue growth, margin expansion, and improved operational metrics, positioning it favourably against both its historical performance and broader market benchmarks."
      },
      {
        "title": "Wockhardt Ltd Surges on High-Value Trading Amid Institutional Interest",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/wockhardt-ltd-surges-on-high-value-trading-amid-institutional-interest-3975598",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/5/WockhardtLtd_most_active_equities_by_value_3975598.png",
        "date": "2026-05-05 10:00:06",
        "description": "Wockhardt Ltd, a prominent player in the Pharmaceuticals & Biotechnology sector, witnessed a remarkable surge in trading activity on 5 May 2026, driven by robust institutional interest and significant value turnover. The stock outperformed its sector and the broader Sensex, reflecting renewed investor confidence despite a recent downgrade in its mojo grade."
      },
      {
        "title": "Wockhardt Q4 FY26: Remarkable Turnaround Masks Valuation Concerns",
        "link": "https://www.marketsmojo.com/news/result-analysis/wockhardt-q4-fy26-remarkable-turnaround-masks-valuation-concerns-3975946",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/5/Wockhardt_quaterlyResult_3975946.png",
        "date": "2026-05-05 09:46:48",
        "description": "Wockhardt Ltd., the Mumbai-based pharmaceutical and biotechnology company, delivered a stunning quarterly performance in Q4 FY26, reporting consolidated net profit of ₹166.00 crores—a remarkable turnaround from the ₹25.00 crore loss posted in the same quarter last year. The sequential growth was equally impressive, with profits surging 181.36% quarter-on-quarter from ₹59.00 crores in Q3 FY26. Despite this operational excellence, the stock faces a critical valuation challenge, trading at a steep 181x price-to-earnings multiple that has prompted a \"SELL\" rating from analysts."
      }
    ],
    "total": 436,
    "sid": "256229",
    "stock_news_url": "https://www.marketsmojo.com/news/wockhardt-256229"
  },
  "announcements": [
    {
      "caption": "Announcement under Regulation 30 (LODR)-Press Release / Media Release",
      "datetime": "04-May-2026",
      "details": "Submission pursuant to Regulation 30 (LODR)Regulations 2015- Press Release",
      "source": "BSE"
    },
    {
      "caption": "Announcement under Regulation 30 (LODR)-Change in Management",
      "datetime": "04-May-2026",
      "details": "Change in Senior Management Personnel.",
      "source": "BSE"
    },
    {
      "caption": "Board Meeting Outcome for Outcome Of The Board Meeting Held On 4Th May 2026",
      "datetime": "04-May-2026",
      "details": "Please be informed that the Board of Directors of the Company at its meeting held today i.e. 4th May 2026 inter-alia has approved: i. the Audited Financial Results and Financial Statements Standalone & Consolidated) for the quarter and financial year ended 31st March 2026. Kindly find enclosed herewith: a. March 2026 along with Audit Report issued by M/s. M S K C & Associates LLP Statutory Auditors of the Company on the same (enclosed as Annexure I); and b. Declaration on unmodified opinion on Audit Report (enclosed as Annexure II) ii Enabling proposal for raising of funds subject to consent of the shareholders at the ensuing AGM and such approvals and compliances as may be required.Audited Financial Results (Standalone & Consolidated) for the quarter and financial year ended 31st March 2026",
      "source": "BSE"
    }
  ],
  "corporate_actions": [
    {
      "img": "board-meeting.svg",
      "title": "BOARD MEETING",
      "msg": "<span>No</span> Upcoming Board Meetings",
      "data": []
    },
    {
      "img": "dividend.svg",
      "title": "DIVIDEND",
      "msg": "",
      "data": [
        {
          "txt": "Wockhardt Ltd has declared <strong>200%</strong> dividend, ex-date: 17 Nov 16",
          "dt": "2016-11-17",
          "middle_text": "Dividend Alert"
        }
      ]
    },
    {
      "img": "splits.svg",
      "title": "SPLITS",
      "msg": "No <strong>Splits</strong> history available",
      "data": []
    },
    {
      "img": "bonus.svg",
      "title": "BONUS",
      "msg": "No <strong>Bonus</strong> history available",
      "data": []
    },
    {
      "img": "rights-issues.svg",
      "title": "RIGHTS",
      "msg": "",
      "data": [
        {
          "txt": "Wockhardt Ltd has announced <strong>3:10</strong> rights issue, ex-date: 08 Mar 22",
          "dt": "2022-03-08",
          "middle_text": "Rights Issue"
        }
      ]
    }
  ]
}

News and Views

Wockhardt Ltd Sees Heavy Value Trading Amid Sector Underperformance

2026-05-07 10:00:10

Wockhardt Ltd, a small-cap player in the Pharmaceuticals & Biotechnology sector, witnessed significant trading activity on 7 May 2026, with a total traded value exceeding ₹258 crore. Despite this high-value turnover, the stock underperformed its sector and broader market indices, reflecting a complex interplay of investor sentiment and institutional interest.

Read full news article

Wockhardt Ltd Sees Technical Momentum Shift Amid Strong Price Rally

2026-05-07 08:01:09

Wockhardt Ltd, a small-cap player in the Pharmaceuticals & Biotechnology sector, has witnessed a notable shift in its technical parameters, signalling a transition from a mildly bearish trend to a sideways momentum. Despite this, the stock has surged impressively, gaining 11.9% in a single day and outperforming the broader Sensex across multiple timeframes, reflecting a complex interplay of bullish and bearish technical indicators.

Read full news article

Wockhardt Ltd Valuation Shifts Signal Heightened Price Premium Amid Strong Returns

2026-05-07 08:00:30

Wockhardt Ltd has witnessed a significant shift in its valuation parameters, moving from an already expensive rating to a very expensive classification. This change comes amid a robust price rally that has seen the stock surge over 11.9% in a single day, raising questions about its price attractiveness relative to historical and peer benchmarks in the Pharmaceuticals & Biotechnology sector.

Read full news article

Wockhardt Ltd Sees Robust Trading Activity Amid Strong Price Gains

2026-05-06 10:00:06

Wockhardt Ltd, a small-cap player in the Pharmaceuticals & Biotechnology sector, has emerged as one of the most actively traded stocks by value on 6 May 2026. The stock recorded a significant 7.56% gain on the day, driven by robust institutional participation and a surge in large order flows, signalling renewed investor confidence despite a recent downgrade in its mojo grade.

Read full news article

Wockhardt Ltd Surges 7.11% to Day's High of Rs 1650 — Outperforms Sector by 6.14 Percentage Points

2026-05-06 09:55:44

The Sensex edged up 0.33% on 6 May 2026, while Wockhardt Ltd surged 7.11%, reaching an intraday high of Rs 1650. This 6.14-percentage-point outperformance over the Pharmaceuticals & Biotechnology sector highlights a distinctly stock-specific rally rather than a broad market lift.

Read full news article

Are Wockhardt Ltd latest results good or bad?

2026-05-05 19:14:29

Wockhardt Ltd's latest financial results for the quarter ended March 2026 highlight a significant operational turnaround for the company. The net profit reached ₹166 crore, reflecting a substantial increase compared to the previous quarter's loss. This marks a notable recovery from prior financial struggles, indicating improved operational efficiency and profitability. The company's revenue also showed positive momentum, with net sales of ₹965 crore, representing an 8.67% increase from the previous quarter and a 29.88% year-on-year growth. This growth is attributed to strengthening demand across its pharmaceutical portfolio and enhanced market penetration. The operating margin improved to 23.32%, the highest in recent quarters, showcasing effective cost management and operational leverage. Wockhardt's transformation from a chronic loss-maker to a profitable entity is underscored by its ability to achieve...

Read full news article

Wockhardt Ltd Reports Outstanding Q4 2026 Performance Amid Strong Financial Trend Reversal

2026-05-05 11:00:05

Wockhardt Ltd has delivered an exceptional quarterly performance for March 2026, marking a significant turnaround in its financial trend from very positive to outstanding. The pharmaceutical company’s latest results showcase robust revenue growth, margin expansion, and improved operational metrics, positioning it favourably against both its historical performance and broader market benchmarks.

Read full news article

Wockhardt Ltd Surges on High-Value Trading Amid Institutional Interest

2026-05-05 10:00:06

Wockhardt Ltd, a prominent player in the Pharmaceuticals & Biotechnology sector, witnessed a remarkable surge in trading activity on 5 May 2026, driven by robust institutional interest and significant value turnover. The stock outperformed its sector and the broader Sensex, reflecting renewed investor confidence despite a recent downgrade in its mojo grade.

Read full news article

Wockhardt Q4 FY26: Remarkable Turnaround Masks Valuation Concerns

2026-05-05 09:46:48

Wockhardt Ltd., the Mumbai-based pharmaceutical and biotechnology company, delivered a stunning quarterly performance in Q4 FY26, reporting consolidated net profit of ₹166.00 crores—a remarkable turnaround from the ₹25.00 crore loss posted in the same quarter last year. The sequential growth was equally impressive, with profits surging 181.36% quarter-on-quarter from ₹59.00 crores in Q3 FY26. Despite this operational excellence, the stock faces a critical valuation challenge, trading at a steep 181x price-to-earnings multiple that has prompted a "SELL" rating from analysts.

Read full news article

View All News